Dentsply (XRAY) Reports Q4 Earnings: What Key Metrics Have to Say

Dentsply International (XRAY) reported $961 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 6.2%. EPS of $0.27 for the same period compares to $0.26 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $920.05 million, representing a surprise of +4.45%. The company delivered an EPS surprise of -3.57%, with the consensus EPS estimate being $0.28.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Dentsply performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales- Connected Technology Solutions: $299 million versus $284.22 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.
• Net sales- Wellspect Healthcare: $88 million versus the five-analyst average estimate of $86.48 million. The reported number represents a year-over-year change of +8.6%.
• Net sales- Orthodontic and Implant Solutions: $202 million compared to the $196.84 million average estimate based on five analysts. The reported number represents a change of +9.2% year over year.
• Net sales- Essential Dental Solutions: $372 million versus the five-analyst average estimate of $348.19 million. The reported number represents a year-over-year change of +7.5%.

View all Key Company Metrics for Dentsply here>>>

Shares of Dentsply have returned +4% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research